| Objective To investigate the clinical effect of ceftriaxone sodium combined with aripiprazole in the treatment of neurosyphilis. Methods Seventy-eight neurosyphilis patients in the Zibo First Hospital from January 2014 to February 2019 were selected and randomly divided into control group (n=39) and observation group (n=39). The control group was treated with penicillin combined with aripiprazole, and the observation group was treated with ceftriaxone sodium combined with aripiprazole. All patients have completed 4 weeks of treatment and 12 months of follow-up. The positive and negative syndrome scale (PANSS) score, the clinical global impression - severity of illness (CGI-SI) score, the percentage of T cells, cytokine levels, adverse reactions and recurrence were compared between 2 groups. Results After 4 weeks of treatment, the observation group had a significant decline of negative symptom scores, positive symptom scores, general psychopathological symptom scores and PANSS total scores than the control group (P＜0.05); and a significant increase of CD3+ T cells, CD4+ T cells, CD4+/CD8+ T cells, IL-2, IL-12 levels than the control group (P＜0.05); the CGI-SI scores of the observation group at 1, 2, 3 and 4 weeks of treatment were lower than those of the control group (P＜0.05); the recurrence rate of the observation group at 6 months and 12 months after the end of treatment was lower than that of the control group (P＜0.05). Conclusions In the treatment of neurosyphilis patients, ceftriaxone sodium can improve the neurological symptoms of patients, reduce the clinical symptom score, increase the percentage of T cells, improve the level of cytokines, reduce the recurrence rate after treatment and show a high safety. Therefore it deserves clinical promotion and application. |